Form 4: Quest Diagnostics SVP Reports Stock Award & Planned Sale

Quest Diagnostics SVP Patrick Plewman reported the settlement of a performance stock award, subsequent tax withholding, and a planned sale of common stock.

Summary

• Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported changes in his beneficial ownership.
• On March 4, 2026, Mr. Plewman acquired 5,682 shares of common stock at a price of $204.86 per share, resulting from the settlement of a performance stock award.
• Also on March 4, 2026, 2,827 shares of common stock were disposed of at $204.86 per share to cover tax withholding obligations related to the performance stock award settlement.
• On March 5, 2026, Mr. Plewman sold 2,855 shares of common stock at a price of $206.21 per share, executed pursuant to a Rule 10b5-1 sales plan.
• Following these transactions, Mr. Plewman's direct beneficial ownership of Quest Diagnostics common stock stands at 15,198 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While the receipt of a performance award is positive, the subsequent sale, even if planned, slightly offsets this. It's a routine insider disclosure.

Positives

• The reporting person, Patrick Plewman, received 5,682 shares of common stock as a settlement of a performance stock award, indicating achievement of performance metrics.

Negatives

• The reporting person disposed of a total of 5,682 shares (2,827 for tax withholding and 2,855 through a planned sale), reducing his overall direct beneficial ownership.

Risks

• Insider selling, even when pre-planned under Rule 10b5-1, can sometimes be perceived negatively by investors, potentially signaling a lack of confidence, though this is a routine transaction.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders, detailing changes in their beneficial ownership. The use of a Rule 10b5-1 plan for sales is a common practice among executives to avoid accusations of insider trading by pre-scheduling transactions.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in insider ownership. The sale of shares, even under a 10b5-1 plan, slightly reduces insider alignment, but the initial award receipt is positive.

Key Dates

Keywords

DGX, Quest Diagnostics, Form 4, insider transaction, stock award, 10b5-1 plan, Patrick Plewman, beneficial ownership